Your browser doesn't support javascript.
loading
Identification of Tissue of Origin and Guided Therapeutic Applications in Cancers of Unknown Primary Using Deep Learning and RNA Sequencing (TransCUPtomics).
Vibert, Julien; Pierron, Gaëlle; Benoist, Camille; Gruel, Nadège; Guillemot, Delphine; Vincent-Salomon, Anne; Le Tourneau, Christophe; Livartowski, Alain; Mariani, Odette; Baulande, Sylvain; Bidard, François-Clément; Delattre, Olivier; Waterfall, Joshua J; Watson, Sarah.
Afiliación
  • Vibert J; INSERM U830, Équipe Labellisée Ligue Nationale Contre le Cancer, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Center, Paris, France.
  • Pierron G; Somatic Genetics Unit, Department of Genetics, Institut Curie Hospital, Paris, France.
  • Benoist C; Clinical Bioinformatic Unit, Department of Diagnostic and Theranostic Medecine, Institut Curie Hospital, Paris, France.
  • Gruel N; INSERM U830, Équipe Labellisée Ligue Nationale Contre le Cancer, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Center, Paris, France; Department of Translational Research, PSL Research University, Institut Curie Research Center, Paris, France.
  • Guillemot D; Somatic Genetics Unit, Department of Genetics, Institut Curie Hospital, Paris, France.
  • Vincent-Salomon A; Department of Diagnostic and Theranostic Medecine, Institut Curie Hospital, Paris, France.
  • Le Tourneau C; Department of Drug Development and Innovation, INSERM U900, Paris-Saclay University, Institut Curie Hospital and Research Center, Paris and Saint-Cloud.
  • Livartowski A; Department of Medical Oncology, Institut Curie Hospital, Paris, France.
  • Mariani O; Department of Diagnostic and Theranostic Medecine, Institut Curie Hospital, Paris, France.
  • Baulande S; Institut Curie Genomics of Excellence (ICGex) Platform, PSL Research University, Institut Curie Research Center, Paris, France.
  • Bidard FC; Department of Medical Oncology, Institut Curie Hospital, Paris, France; INSERM CIC-BT 1428, UVSQ, Paris-Saclay University, Saint-Cloud, France.
  • Delattre O; INSERM U830, Équipe Labellisée Ligue Nationale Contre le Cancer, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Center, Paris, France; Somatic Genetics Unit, Department of Genetics, Institut Curie Hospital, Paris, France.
  • Waterfall JJ; Department of Translational Research, PSL Research University, Institut Curie Research Center, Paris, France; INSERM U830, PSL Research University, Institut Curie Research Center, Paris, France.
  • Watson S; INSERM U830, Équipe Labellisée Ligue Nationale Contre le Cancer, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Center, Paris, France; Department of Medical Oncology, Institut Curie Hospital, Paris, France. Electronic address: sarah.watson@curie.fr
J Mol Diagn ; 23(10): 1380-1392, 2021 10.
Article en En | MEDLINE | ID: mdl-34325056
ABSTRACT
Cancers of unknown primary (CUP) are metastatic cancers for which the primary tumor is not found despite thorough diagnostic investigations. Multiple molecular assays have been proposed to identify the tissue of origin (TOO) and inform clinical care; however, none has been able to combine accuracy, interpretability, and easy access for routine use. We developed a classifier tool based on the training of a variational autoencoder to predict tissue of origin based on RNA-sequencing data. We used as training data 20,918 samples corresponding to 94 different categories, including 39 cancer types and 55 normal tissues. The TransCUPtomics classifier was applied to a retrospective cohort of 37 CUP patients and 11 prospective patients. TransCUPtomics exhibited an overall accuracy of 96% on reference data for TOO prediction. The TOO could be identified in 38 (79%) of 48 CUP patients. Eight of 11 prospective CUP patients (73%) could receive first-line therapy guided by TransCUPtomics prediction, with responses observed in most patients. The variational autoencoder added further utility by enabling prediction interpretability, and diagnostic predictions could be matched to detection of gene fusions and expressed variants. TransCUPtomics confidently predicted TOO for CUP and enabled tailored treatments leading to significant clinical responses. The interpretability of our approach is a powerful addition to improve the management of CUP patients.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Primarias Desconocidas / Transcriptoma / Aprendizaje Profundo / RNA-Seq Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Mol Diagn Asunto de la revista: BIOLOGIA MOLECULAR Año: 2021 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Primarias Desconocidas / Transcriptoma / Aprendizaje Profundo / RNA-Seq Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Mol Diagn Asunto de la revista: BIOLOGIA MOLECULAR Año: 2021 Tipo del documento: Article País de afiliación: Francia